We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




BD Sells Surgical Instrumentation Platform to STERIS

By HospiMedica International staff writers
Posted on 21 Jun 2023
Print article
Image: The divestiture of the surgical instrumentation platform includes V. Mueller, Snowden-Pencer and Genesis branded products (Photo courtesy of BD)
Image: The divestiture of the surgical instrumentation platform includes V. Mueller, Snowden-Pencer and Genesis branded products (Photo courtesy of BD)

Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) has signed a definitive agreement to sell its Surgical Instrumentation platform to STERIS (Mentor, OH, USA) for USD 540 million. The divestiture includes the transfer of V. Mueller, Snowden-Pencer, and Genesis branded products as well as three manufacturing facilities.

STERIS is a global provider of products and services that support patient care, particularly in the field of infection prevention. It offers a wide range of infection prevention products and other procedural services, mainly aimed at healthcare, pharmaceutical, medical device, and dental clients. The acquisition of BD's surgical instrumentation platform, which complements STERIS's Healthcare segment, will empower STERIS to more effectively meet the product and service demands of hospitals and surgery centers. The platform has three dedicated manufacturing sites and about 20,000 SKUs in its portfolio. The divestment of its Surgical Instrumentation platform aligns with the "Simplify" objective of BD's 2025 strategy and represents a significant move towards streamlining its product portfolio and manufacturing network.

"The Surgical Instrumentation platform has a 120-year legacy of providing reliable and trusted high-quality products, and STERIS is well positioned to maximize the value of this extensive portfolio and is fortunate to be adding such a dedicated and talented team to its organization," said Rick Byrd, president of the Interventional segment at BD. "This transaction further advances the BD Interventional segment's focus on high-growth end markets. We look forward to continuing to address unmet needs in health care through a highly differentiated and innovative set of solutions and products."

Related Links:
Becton, Dickinson and Company 
STERIS 

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Video Uretero-Renoscope
Olympus URF-V3/V3R
New
Coronary Stent System
Ultimaster Sirolimus

Print article

Channels

Critical Care

view channel
Image: The new technology can make heart-related predictions more widely accessible through the use of wearables (Photo courtesy of Fred Zwicky/UIUC)

Wearable Technology Predicts Cardiovascular Risk by Continuously Monitoring Heart Rate Recovery

The heart's response to physical activity is a vital early indicator of changes in health, particularly in cardiovascular function and mortality. Extensive research has demonstrated a connection between... Read more

Surgical Techniques

view channel
Image: The diffusion model was trained on real LGE-MRI distributions and generated synthetic fibrosis distributions from Gaussian noise (Photo courtesy of Frontiers, DOI: 10.3389/fcvm.2025.1512356)

AI-Generated Synthetic Scarred Hearts Aid Atrial Fibrillation Treatment

Atrial fibrillation (AF) is a common heart rhythm disorder, often linked to the development of fibrosis, which is the formation of scar tissue in the heart. This fibrosis typically arises due to aging,... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.